Skip to main content

Table 1 Input data in the mathematical model

From: Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?

  Parameter Value References
Vaccination Cohort size 281,000 [53]
Global vaccine efficacy CC (proxy CIN3+) 93 % [12]
Global vaccine efficacy CIN2/3 (proxy CIN2+) 65 % [12]
Global vaccine efficacy CIN1 (proxy CIN1+) 50 % [12]
Age at vaccination 11, 15 or 25 years Assumed
Vaccine waning None Assumed
Screening Screening age range 25 to 64 years [32]
Screening interval every 3 years [32]
Percentage screened 65 % [32]
Percentage never screened 35 % [32]
Cytology sensitivity 58–61 % [54]
Compliance to CIN 1 treatment 37 % [32], expert opinion
Compliance to CIN 2/3 treatment 100 % [32], expert opinion
Efficacy of CIN treatment 90 % [32], expert opinion
Transition Probabilities Healthy to HPV 0.07 [55]
HPV to CIN 1 0.05 [56]
CIN 1 to CIN 2/3 0.09 [5759]
CIN 2/3 to persistent CIN 2/3 0.11 [57, 59]
HPV clearance to healthy 0.45 [6064]
CIN 1 clearance 0.24 [5759]
CIN 2/3 clearance 0.23 [57, 59]
Persistent CIN 2/3 to CC 0–0.06 Calibrated
  1. CC cervical cancer, CIN cervical intraepithelial neoplasia, HPV Human Papillomavirus